Trialbee Secures Majority Investment to Enhance Global Trial Recruitment

Clinical trial recruitment specialist Trialbee has received a significant majority investment from Varsity Healthcare Partners. This strategic move aims to bolster Trialbee’s technology and global delivery capabilities amidst growing challenges in trial enrollment faced by biopharma companies.

The financial specifics of the investment remain undisclosed, but it provides Varsity Healthcare Partners with a controlling stake in the company. Existing investors, MTIP and Industrifonden, will continue as minority stakeholders. The influx of capital is set to expedite the expansion of Trialbee’s innovative Honey Platform, enhance enterprise-level recruitment services, and strengthen its international delivery capabilities across various channels.

Matt Walz, Chief Executive Officer of Trialbee, emphasized that this partnership will enable the company to enhance its speed and reliability for sponsors, contract research organizations, and trial sites worldwide. He highlighted the objective of better connecting patients and research sites, thus facilitating timely and budget-compliant study enrollments.

Over the past year, Trialbee has significantly broadened its global reach, now collaborating with over 6,000 research sites in 50 countries and supporting clinical trials in 66 languages. The company reported successfully screening more than 1.5 million patients in 2025, aided by new sponsor-specific registries and strengthened data partnerships designed to optimize patient feasibility and enrollment projections.

Varsity Healthcare Partners focuses on healthcare services and technology companies that support clinical operations on a large scale. Partner Navid Gharavi noted that Trialbee aligns with the firm’s strategy of investing in established platforms that exhibit potential for operational growth. He expressed admiration for Trialbee’s commitment to customer outcomes and its adeptness in applying data to address persistent challenges in clinical research.

This investment arrives during a critical period for biopharma sponsors, who are under increasing scrutiny regarding trial timelines and enrollment effectiveness. As clinical trial protocols become more specialized and eligibility criteria tighten, recruitment failures have emerged as a leading cause of delays and cost overruns.

Despite the changes brought about by this investment, Trialbee has confirmed that its leadership and mission will remain steadfast. Financial advisory firm Stout facilitated the transaction, ensuring a smooth transition as Trialbee embarks on this new growth phase.

With this fresh capital and a new majority owner, Trialbee is poised to emerge as a pivotal partner for sponsors aiming to modernize the processes of patient identification, engagement, and enrollment in clinical trials globally.